DEP irinotecan outperforms in pancreatic cancer model
Filed with ASX · · 4 pages · English
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy
- Annual report and full year financial results
- VivaGel BV NDA advances to next stage of FDA review
- Starpharma licenses VivaGel BV to Mundipharma for Europe
- Mundipharma licenses Starpharmas VivaGel BV
Later from Starpharma
- Starpharma Investor Presentation for Citi Conference
- DEP products outperform in human pancreatic cancer model
- US VivaGel BV licensed for A$142M milestones plus royalties
- US FDA requests further data for VivaGel BV approval
- VivaGel condom receives final regulatory approval in Japan
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma